Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A plant extract and compounds for use in wound healing

A technology of plant extracts and compounds, applied in the direction of plant raw materials, plant/algae/fungus/moss components, drug combinations, etc., can solve the problem of inability to promote skin wound healing in rats

Inactive Publication Date: 2017-09-05
PHYNOVA LTD
View PDF10 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Data (paragraphs linking paragraphs on pages 3 and 4) show that wild-type plant extracts fail to promote wound healing in rat skin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A plant extract and compounds for use in wound healing
  • A plant extract and compounds for use in wound healing
  • A plant extract and compounds for use in wound healing

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] 1.1. Preparation of extract solution

[0111] Applicants dissolved ~10 mg of Salvia m. Bunge extract (as disclosed in WO2009050451 ) in the required volume of 100% ethanol or 100% DMSO to obtain a 1% (w / v) extract solution. They tested 5 μL of this solution (1% final ethanol or DMSO concentration) in a 500 μL assay incubation volume. From this 1% solution of Danshen extract, they also prepared 1:10 and 1:100 dilutions in 100% ethanol or 100% DMSO. From these solutions, they tested 5 μL in a 500 μL assay incubation volume.

[0112] 1.2. Determination of CYP11B1

[0113] The V79MZh11B1 cell line expressing recombinant human CYP11B1 was supplemented with 5% fetal calf serum (FCS; Sigma), penicillin G (100 U / ml), streptomycin (100 μg / ml), glutamine (2 mM) and sodium pyruvate (1mM) Dulbecco modified Eagle (DME, Sigma)) at 37°C, 5% CO 2 Cultivate in the air. Cells were placed on a 24-well cell culture plate (8 × 10 per well 5 cells) and cultured to confluency in 1 ml D...

Embodiment 2

[0127] MTT cell viability assay

[0128] Place V79MZh11B1 cells on 1ml DME medium in a 24-well cell culture plate (8×10 per well 5 cells) were grown to confluence. On the day of the test, the DME medium was removed, and 450 μl of fresh DME medium containing 5% FCS (containing 5 μl of Danshen extract solution in 100% ethanol) was added to each well. Ethanol (1%) and Triton X-100 (0.0006%) were used as vehicle and positive control, respectively (all final concentrations). All measurements were performed in quadruplicate. At 37°C, 5% CO 2 After incubation for 60 min, 50 μl of fresh DME medium (+5% FCS) was added to each well. After 25 min, the medium was replaced with 500 μl of fresh DME medium (+5% FCS), and 25 μl of MTT solution (5 mg / ml PBS, pH 7.2) was added thereto immediately. After 30 min, all medium was removed and cells were lysed in 250 μl of 0.5% acetic acid (v / v), 10% SDS (w / v) in DMSO. Measuring formazan by spectrophotometry at a wavelength of 570 nm (formaza...

Embodiment 3

[0136] Considering the activity of the extracts, applicants used the methodology described in Example 1 to observe the activity of some of the tanshinones.

[0137] The tanshinones tested in V79MZh11B1 cells were:

[0138] ●Tanshinone IIA;

[0139] ●Tanshinone I;

[0140] ● Dihydrotanshinone I; and

[0141] ● Cryptotanshinone.

[0142] The results are shown in Table 3 below:

[0143] table 3.

[0144]

[0145] table 3. CYP11B1 inhibition by tanshinone IIA, tanshinone I, dihydrotanshinone I, and cryptotanshinone. Results are mean ± SD of 2 independent experiments.

[0146] As apparent from the results, each tanshinone showed inhibitory activity, the two most potent being dihydrotanshinone (94% inhibition at 10 μM) and tanshinone I (64% inhibition at 10 μM).

[0147] This in itself was unexpected as these two compounds were present in lower amounts in the extract disclosed in WO2009050451 (3.65% and 3.82%, respectively) than cryptotanshinone and tanshinone IIa (18.95...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention relates to the use of a plant extract, derived from a Salvia spp, comprising one or more tanshinone compounds, or said one or more tanshinone compounds, in the treatment of wounds, particularly chronic wounds, or other conditions benefiting from inhibition of Cortisol production, particularly Cushing's syndrome. Preferred tanshinone compounds include, but are not limited to, dihydrotanshinone (particularly 15,16- dihydrotanshinone (CAS No. 87205-99-0) ) and Tanshinone I.

Description

[0001] The present invention relates to plant extracts comprising one or more tanshinone compounds or said one or more tanshinone compounds derived from species of the genus Salvia (Salvia spp) for use in the treatment of wounds, in particular chronic wounds or Other conditions that benefit from suppressed cortisol production, notably Cushing's syndrome. [0002] Preferred tanshinone compounds include, but are not limited to, dihydrotanshinone (especially 15,16-dihydrotanshinone (CAS No. 87205-99-0)) and Tanshinone I. [0003] Preferred treatments include treating chronic wounds (generally defined as wounds that take more than 6 weeks to heal). Such wounds are especially common in obese patients and patients with diabetes, as well as in bedridden patients (decubitus or bedsores) and patients who have undergone external beam radiation therapy. [0004] Chronic wounds fail to heal in an orderly set of stages and in a predictable amount of time (the way most wounds experience). C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/537A61K31/58A61P17/02A61P9/14
CPCA61K31/58A61K36/537A61K2300/00A61P5/46A61P9/14A61P17/02A61P35/00A61K31/343A61Q11/00A61K8/9789A61K47/6955
Inventor A·B·加拉格尔R·W·哈特曼M·恩格尔A·科克C·J·范柯鹏
Owner PHYNOVA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com